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Abstract
Background: Although non-ischemic troponin elevation is frequently seen in patients admitted to the emergency 
department (ED), consensus regarding its management is lacking. 
Objectives: This study aimed to characterize patients admitted to the ED with non-ischemic troponin elevation and to 
identify potential mortality predictors in this population.
Methods: This retrospective observational study included ED patients with a positive troponin test result between June and 
July of 2015. Patients with a clinical diagnosis of acute coronary syndrome (ACS) were excluded. Data on patient demographics 
and clinical and laboratory variables were extracted from medical records. Follow-up data were obtained for 16 months or 
until death occurred. The statistical significance level was 5%.
Results: Troponin elevation without ACS was found in 153 ED patients. The median (IQR) patient age was 78 (19) years, 
80 (52.3%) were female and 59(38.6%) died during follow-up. The median (IQR) follow-up period was 477(316) days. 
Survivors were significantly younger 76 (24) vs. 84 (13) years; p=0.004) and featured a higher proportion of isolated 
troponin elevation (without creatine kinase or myoglobin elevation) in two consecutive evaluations: 48 (53.9%) vs. 8 
(17.4%), p<0.001. Survivors also presented a lower rate of antiplatelet treatment and same-day hospitalization. In the 
multivariate logistic regression with adjustment for significant variables in the univariate analysis, isolated troponin 
elevation in two consecutive evaluations showed a hazard ratio= 0.43 (95%CI 0.17–0.96, p=0.039); hospitalization, 
previous antiplatelet treatment and age remained independently associated with mortality.
Conclusions: Isolated troponin elevation in two consecutive measurements was a strong predictor of survival in ED 
patients with troponin elevation but without ACS. (Arq Bras Cardiol. 2021; 116(5):928-937)
Keywords: Troponin I; Prognosis; Emergency Department; Myocardial Non-Ischemic Injury.
cTn is a protein distributed within the cytoplasm and 
sarcomere of a cardiac myocyte, mostly in the sarcoplasmic 
reticulum. Three subunits make up the troponin complex, 
an inhibitory component (troponin I), tropomyosin-binding 
component (troponin T) and calcium-binding component 
(troponin C).4
The T and I subunits (cTnT and cTnI, respectively) are 
specific to cardiac muscle and, thus, can act as suitable markers 
of cardiac injury. cTnT shows a double discharge, first the 
cytoplasmic component and later the binding component.5 
cTnI is cardiac-specific, and was not identified in skeletal 
muscle. This 100% specificity shows cTnI can be an ideal 
myocardial necrosis marker (MNM).6
Before the advent of troponin, the previous MNM used 
were muscle/brain isoenzyme of creatine kinase (CK-MB) and 
myoglobin, which were less sensitive and not specific to myocardial 
infarction.7,8 Due to their lack of sensitivity and specificity, they have 
been progressively excluded from ACS investigations.2,3
Although cTn subunits are strongly specific to cardiac 
myocytes, they can be released under a wide spectrum of non-
Introduction
Clinical myocardial infarction according to the fourth 
universal definition requires the presence of acute myocardial 
injury detected by abnormal cardiac biomarkers associated 
with evidence of acute myocardial ischemia. Cardiac 
troponin(cTn) above the 99th percentile cutoff point with an 
increasing or decreasing pattern is the biomarker of myocardial 
injury,1 because it cannot be released by non-cardiac tissues 
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cardiac pathological conditions, such sepsis, chronic kidney 
disease, hypertensive emergencies, gastrointestinal bleeding, 
stroke and rhabdomyolysis.6,9 In this setting, the detection 
of troponin may be the result of 5–8% of the cytosolic 
component release in response to myocyte cell turnover, 
cellular release of degradation products, and increased cellular 
wall permeability.10
The widespread use of troponin assays in the emergency 
department (ED) may pose a difficult diagnostic challenge when 
the test is abnormal in patient without an ACS.11According to 
the literature, elevated cTn levels in patients without an ACS 
was associated with a poor prognosis.10,12-16
Objective
This study aimed to identify factors predictive of mortality/
survival in ED patients without ACS and elevated cTnI using 
patient characteristics, clinical past history, comorbidities and 
analytic values (including creatinine, CK-MB, myoglobin and 
cTnI) measured in ED. 
Methods
Study design, setting, and participants
In this retrospective study, we analyzed the laboratory data 
of consecutive patients that came to the ED of a community 
teaching hospital during 1-month period from June to July of 
2015, and selected patients who presented with cTnI elevation.
All clinical information was collected, including medical 
and nursing records of the ED and hospitalizations, analyses, 
and other complementary exams. Follow-up was performed 
through local and national records to observe the rates of 
cardiovascular re-hospitalization and death.
The collected data included demographics, cardiovascular 
risk factors, myocardial biomarker assay and creatinine results, 
main symptom at the ED, final ED diagnosis, hospitalization, 
hospitalization mortality, mortality rate at 30 days and 16 
months, and cardiovascular re-hospitalization rate. 
In this study, the criteria for the diagnosis of acute 
myocardial infarction were an increase or decrease in Troponin 
I with at least one abnormal value higher than the upper 
reference limit of the assay and at least one of the following: 
1) symptoms of ischemia; 2) new ST-segment/ T-wave 
changes or new left bundle-branch block; 3) development of 
pathological Q waves on electrocardiography; 4) new loss of 
viable myocardium or regional wall motion abnormalities on 
imaging test; or 5) identification of an intracoronary thrombus 
on imaging test.1
Emergency and hospitalization registries of all patients 
with elevated cTnI, were revised by the investigators, and 
patients were divided into two groups: those diagnosed with 
an ACS, (Type 1 myocardial infarction(MI) or type 2 with 
ischemic signs and symptoms (with vasospasm, embolism and 
non-atherosclerotic coronary dissection) (group A) and those 
without an ACS with a positive troponin assay due to oxygen 
supply/demand imbalance or myocardial injury with no signs 
or symptoms of acute myocardial ischemia(group B). Patients 
with type 4 or 5 MI were not  included in this study, as by 
definition these are not the regular ED patients, and type 3 
MI patients have no cTnI measure.1
Non-ACS patients were identified by predefined criteria 
that included the following: 1) myocarditis/cardiomyopathy: 
discharge diagnosis or findings suggestive of myocarditis on 
imaging test or pathology, infiltrative cardiomyopathies such 
as amyloidosis or sarcoidosis, an ejection fraction ≤30% prior 
to admission, or prior cardiac transplantation; 2) infections: 
conditions with systemic impact such as cellulitis, pneumonia, 
sepsis, and pyelonephritis; 3) acute dysrhythmias unrelated 
to ACS; 4) chronic or acute kidney disease: stage-5 chronic 
kidney disease, chronic dialysis, renal transplant recipient, 
or moderate to severe acute kidney disease; 5) central 
nervous system pathology: stroke, seizure, or subarachnoid 
hemorrhage; 6) acute abdominal or gastrointestinal bleeding; 
7) pulmonary embolism; 8) unexplained syncope; 9) asthma 
or chronic obstructive pulmonary disease exacerbation; and 
10) others: elevated troponin level of unknown etiology, which 
does not meet any of the abovementioned criteria.
The primary endpoint for this study was mortality during 
hospitalization, at 30 days and 16 months, while the secondary 
endpoint was rehospitalization for cardiovascular disease 
during follow-up.
Follow-up was completed at 16 months or at death. Follow-
up was performed through electronic medical records and the 
online national death registry. The institutional review board 
approved the study protocol. The requirement for informed 
consent was waived, because the patients did not receive any 
type of different care because of the study. 
Myocardial necrosis marker assays
The troponin I level was determined using the same 
standard cTnI immunoassay (Troponin I Siemens Dimension 
EXL)17-19 in all patients. The test was performed in the central 
hospital laboratory. The lower and upper detection limits 
established by the manufacturer were 0.017 ng/mL and 
4000ng/mL, respectively. Measurements below the detection 
limit were assigned a value of 0. Troponin I test results were 
considered positive if the level was higher than the reference 
limit (>0.059 ng/mL) used in the ED laboratory. The CK-
MB and myoglobin assay results were considered normal at 
<3.6ng/mL and at 9–82 ng/mL, respectively. 
Repeated MNM measurements were performed at least 3 
hours after the first evaluation.
Using the first and second evaluation of cardiac troponin, 
the variation was calculated as follows: variation of troponin 
% = ((second troponin × 100)/first troponin) × 100%.
Statistical methods
All continuous data were tested for normality with the 
Shapiro-Wilks test; all showed non-normal distribution 
and are presented as median and interquartile range. The 
Mann-Whitney test was applied to compare continuous 
variables. Categorical variables were represented by their 
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Survival was analyzed using uni- and multivariate Cox 
proportional hazard models. The results were expressed as 
hazard ratio (HR) with 95% confidence intervals (95%CI). For 
the independent survival predictor variables, a survival plot 
was obtained using the Kaplan-Meier method and the log-rank 
test. The statistical significance level was set at p-value<0.05. 
All statistical analyses were performed using SPSS 23.0 for Mac 
(SPSS, Inc; Chicago, IL, USA).
Results
Baseline characteristics and diagnoses of the study 
population
During the one-month study period, 10,564 patients were 
admitted to our institution’s ED. Patients who underwent MNM 
evaluations including troponin I, CK-MB, and myoglobin and 
their distribution according to troponin status and final diagnosis 
are described in Figure 1. Patients were assigned to two groups: 
Group A (n=42 [21.5%]) with ACS (all of them with acute 
occlusion/subocclusion of coronary arteries: 4 of them with type 
2 MI (2 coronary dissection and 2 embolic coronary thrombosis); 
of 38 with type 1 MI, 14 with acute MI with ST-elevation (STEMI)); 
while in Group B (n=153 [78.5%]) with Non-ACS, 58 had 
oxygen supply/demand imbalance, 53 had acute myocardial 
injury without sign or symptoms of ischemia and 42 had stable 
elevation of cTnI (cTnI variation on two consecutive analysis ≤ 
20%). Among the Non-ACS patients, the first measure of MNM 
was performed after a median of 6 (IQR 4) hours since symptom 
onset, and 90 patients had the MNM measure repeated after a 
median of 5 (IQR 3) hours since the first evaluation.
On the first MNM evaluation of group B, 81 had CKMB 
and/or myoglobin elevation (16 showed CKMB and 40 showed 
myoglobin elevation, whereas 25 showed elevation of both). 
On the second evaluation, 18 showed elevation of both and 6 
showed isolated elevation of CKMB and 31 of myoglobin. At 
both evaluations, 88 patients showed at least one elevation of 
CKMB and/or myoglobin.
Patients with a positive troponin test result had a wide 
spectrum of clinical symptoms at presentation (Figure 2). 
As expected, patients who ultimately received a diagnosis of ACS 
(Group A) had a higher proportion of chest pain as the main 
complaint at hospital presentation.
As shown on Table 1, patients in Groups A and B had a similar 
median age but had significantly different gender proportions. 
Concerning cardiovascular risk factors and comorbidity 
conditions, no significant differences were found in the prevalence 
of diabetes mellitus and hypertension, but hyperlipidemia and 
previous coronary artery disease were more common in the ACS 
patients and previous heart failure and anticoagulant treatment 
were more prevalent in Non-ACS patients. 
The main diagnoses in Group B patients were myocarditis/
cardiomyopathy (40[26%]), followed by infection (cellulitis, 
pneumonia, and pyelonephritis, 24[15.5%]), acute dysrhythmias 
(25 [16.6%]), chronic or acute kidney disease (17 [11%]), cerebral 
disease (13 [8.4%]), acute abdominal or gastrointestinal bleeding 
(11 [7.1%]), pulmonary embolism (6 [3.9%]), unexplained 
syncope (4[2.6%]), asthma or chronic obstructive pulmonary 
disease exacerbation (4 [2.6%]), and others (9 [6.5%]).
Outcome data
The median (IQR) follow-up was 477 days (316). No significant 
intergroup differences were found regarding in-hospital mortality 
(6 [14.3%] vs. 21 [13.7%], p=0.077), 30-day mortality (6 [14.3%] 
vs. 27 [17.6%], p=0.4) and cardiovascular rehospitalization at 
follow-up (11 [29.7%] vs 32 [24.2%], p=0.316). Remarkably, 
the long-term mortality rate was significantly higher in group 
B patients (9 [21.4%] vs. 59 [38.6%], p=0.039), although the 
survival curves of the two groups were not significantly different 
(log rank, 3.45; p=0.063). The main causes of death in group 
B were cardiovascular in 12 individuals (none of them with a 
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diagnosis of acute myocardial infarction), non-cardiovascular in 
27, 13 unknown causes and 4 due to mixed of cardiovascular 
and other comorbidity.
Main results
Predictors of mortality in Group B patients are described 
in Table 2. We found that older age (p<0.001), previous 
heart failure (p=0.049), previous antiplatelet medication 
(p=0.005) and hospitalization after index ED evaluation 
(p<0.001) were mortality predictors. Death at follow-up was 
not related to cTnI, CK-MB, or myoglobin levels (first, second, 
or both evaluations). However, isolated troponin elevation 
(i.e., without concomitant CK-MB or myoglobin elevation) 
was a powerful predictor of survival; in fact, isolated troponin 
elevation at the first measurement was present in 58.7% of 
survivors vs. 40% of non-survivors (p=0.021); patients with 
two isolated troponin elevation measurements were more 
likely to survive (48 [53.9%] of survivors vs. 8[17.4%] of non-
survivors [p<0.001]). 
Cox regression analysis is shown on Table 3. The univariate 
analysis showed that in inpatients with isolated troponin 
in two consecutive MNM measurements, the probability 
of long-term survival at follow-up increased by four-fold 
(p<0.001). Cox multivariate analysis corrected for age and 
gender demonstrated that isolated troponin elevation in 
two consecutive measurements remained an independent 
predictor of survival (HR, 0.433; 95%CI, 0.196–0.958; 
p=0.039). Figure 3 shows the survival curves of Group B 
patients according to the presence of isolated troponin 




In our study, 78% of patients with troponin elevations received 
a non-ACS diagnosis, which is in agreement with previous 
studies.20,21 In some series, myocardial ischemia was not identified 
in approximately 65% of ED patients with troponin elevation. The 
spectrum of clinical diagnosis was extremely heterogeneous in our 
study, encompassing high-risk conditions. Mid-term prognosis was 
clearly worse for patients with elevated troponin and non-ACS 
than for patients with normal troponin levels. It was also probably 
worse than for patients diagnosed with ACS, with these findings 
having been reported in previous studies.16,22,23
In this study, 33.5% of the patients with elevated troponin 
levels and a non-ACS diagnosis were discharged from the ED 
without hospitalization. This percentage seems very high, but 
higher rates have been described by other authors.21,24,25 In the 
non-ACS group, the 16-month mortality rate was 38.6%, but 
81.4% of these deaths occurred during hospitalization or during 
the first 30 days, which reinforces the role of MNM as a mortality 
predictor in this group. Considering the high hospital discharge 
rate after an ED stay and the high risk of mortality conferred by 
troponin elevation, it is not surprising that elderly patients with 
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troponin elevation who receive a diagnosis other than ACS and 
are not admitted to the hospital are at an unacceptable high 
risk of death.
We believe that the high mortality rate during hospitalization 
and follow-up is closely related to older age and greater 
comorbidities (past heart failure or antiplatelet medication), as 
reported by others.21
The only biomarker recommended to diagnose ACS 
at this time is cardiac troponin, due to its higher sensitivity 
and accuracy.2,3 In fact, up to 80% of patients with ischemic 
myocardial infarction will have an elevated troponin level within 
2–3 hours after ED arrival.7
Our study is remarkable for finding that isolated cTnI elevation 
in two consecutive analyses of MNMs is a survival predictor 
for patients with cTnI elevation and non-ACS, compared to 
the elevation in at least two MNMs (cTnI and CK-MB and/or 
myoglobin). Some particularities of the different properties of 
MNM molecules could explain this fact. Myoglobin has an early 
release and quick clearance (released starting 1h after the injury 
and return to baseline at 24–36h), while CK-MB shows  slower 
release and clearance (release starting 4–9h after the injury and 
clearance after 48–72h),26 and troponin shows a release similar 
to that of CK-MB (4–9h) but delayed clearance (7–10 days).27 
We hypothesize that the persistent elevation of CK-MB and/
or myoglobin along with troponin in two consecutive MNM 
analyses implies a recent or permanent myocardial injury, even 
in non-ACS patients. 
Probably, there was a difference in the release mechanism 
of different MNM molecules according to the injury type and 
severity. Some studies in animals and human cells suggested that 
the discharge of myocardial proteins just like cTn may not imply 
myocardial necrosis.28
Regarding the T and I subunits, cTnI has a molecular weight 
of 37 kDa and cTnT has a molecular weight of 21 kDa; both 
presenting mainly in the sarcomeres and 4–6% in the cytoplasm. 
After the myocardial injury, cytosolic troponin is released first; as 




n = 42 (22%)
Group B
n = 153 (78%) p Value
Age (years), median(IQR) 77(21) years 71(19) years 78(19) years 0.06
Male n (%) 105 (53.8%) 32 (76.2%) 73 (47.7%) 0.001
Diabetes mellitus, n (%) 69 (35.5%) 16 (37.2%) 54 (35%) 0.89
Hypertension, n (%) 155 (79.3%) 35 (84.4%) 119 (78.1%) 0.57
Hyperlipidemia, n (%) 87 (44.4%) 25 (60%) 61 (40.1%) 0.03
Previous CAD, n (%) 37 (19%) 13 (31%) 24 (16%) 0.02
Previous HF, n (%) 43 (21.9%) 9 (21.9%) 71 (46.7%) 0.02
Previous AIS, n (%) 31 (14.8%) 3 (6.3%) 26 (16.8%) 0.26
GFR (ml/[min⋅1.73 m2]), median(IQR) 54 (46) 68 (47) 49(47) 0.10
Previous Medications
Anticoagulants 62 (33.7%) 4 (10%) 47 (31%) 0.007
Antiplatelets 50 (26.7%) 15(37%) 48 (32%) 0.13
Beta-blockers 69 (36.9%) 16 (40%) 53 (36.1%) 0.65
ACE inhibitors/AARA 108 (57.8%) 23 (57.5%) 87 (57.8%) 0.97
MRA 15 (17.6%) 2 (12.5%) 13 (18.8%) 0.55
Statins 83 (44.4%) 24 (60%) 60 (40.1%) 0.02
Standardized troponin at the first evaluation*, n (%) <0.001
1–2.99 95 (48.9%) 10 (23.1%) 85 (55.8%)
3–4.99 36 (18.3%) 5 (12.8%) 31 (19.7%)
5–9.99 19 (9.7%) 4 (10.3%) 15 (9.7%)
10+ 45 (23.1%) 23 (53.8%) 22 (15%)
Elevated CK-MB, n(%) 54 (53%) 22 (53%) 32 (21%) <0,001
Elevated  myoglobin, n(%) 88 (48%) 23 (56%) 66 (45%) 0,24
Elevated CK-MB + Myoglobin, n(%) 43 (22%) 16 (40%) 25 (16%) 0,003
% troponin elevation between 2 measurements, median (IQR) 7 (73) 183 (666) 2,65(42) <0.001
Group A- patients with acute coronary syndrome (ACS); Group B- patients without ACS. CAD: coronary artery disease; HF: heart failure; AIS: acute 
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Table 2 – Association between Clinical Variables and Long-Term Survival of Patients with Troponin  Elevation and Non-Acute 
Coronary Syndrome (Group B)
Survivors 
(n = 94) Non-survivors (n = 59) p-value  
Age, median (IQR) 76(24) years 84 (13) <0.001
Male, n(%) 44 (46.8%) 29 (49.2%) 0.77
CV Risk Factors, n(%)
Diabetes mellitus 28 (30.8%) 22 (38.6%) 0.33
Hypertension 68 (73.9%) 44 (78.6%) 0.52
Previous CAD 14 (15.2%) 9 (16.4%) 0.85
Previous HF 33 (39.3%) 31 (56.4%) 0.049
GFR, mL/(min⋅1.73 m2), median(IQR) 56 (48) 45 (34) 0,05
Heart rate, bpm, median(IQR) 75 (33) 84 (36) 0.10
Previous Medication, n (%)
Antiplatelets 22 (23.9%) 25 (35.5%) 0.02
Anticoagulants 34 (37%) 12 (21.8%) 0.06
Beta-blockers 35 (38%) 18 (32.7%) 0.52
ACE inhibitors 57 (62%) 28 (50.9%) 0.19
MRA 9 (20.5%) 4 (16%) 0.65
Statins 36 (39.1%) 23 (41.8%) 0.75
ECG, n (%)
No significant alterations 51 (64.6%) 16 (50%)
0.38
ST elevation 1 (1.3%) 0 (0%)
ST-depression or negative T-wave 16 (20.3%) 6 (18.8%)
Atrial fibrillation 28 (35.0%) 18 (46.2%)
LBBB 4 (5.1%) 4 (12.5%)
Pace rhythm 4 (5.1%) 3 (9.4%)
Myocardial Necrosis Markers, median (IQR) 
Troponin (ng/mL) at the first evaluation 0,13 (0,23) 0,10 (0,18) 0.61
CK-MB (ng/mL) at the first evaluation 1,6 (1,8) 1,9 (2,05) 0.50
Myoglobin (ng/mL) at the first evaluation 70 (120) 99 (175) 0.06
Isolated troponin elevation at the first evaluation, n (%) 54 (58.7%) 22 (40%) 0.028
Troponin (ng/mL) at the second evaluation, median (IQR) 0,12(0,16) 0,14(0,32) 0,28
% troponin I variation on two sequential measurements, 
median (IQR)
0 (32) 27 (35) 0.002
Isolated troponin elevation at two sequential 
measurements, n(%)
48 (53.9%) 8 (17.4%) <0.001
Hospitalization at index event, n(%) 52 (55.3%) 51 (86.4%) <0.001
Coronary revascularization 0.88
No specific therapy, n(%) 88 (93.6%) 54 (91.5%)
OMT, n(%) 5 (5.3%) 4 (6.8%)
PCI + OMT, n(%) 1 (1.1%) 1 (1.1%)
IQR: interquartile range; CAD: coronary artery disease; HF: heart failure; AIS: acute ischemic stroke; GFR: glomerular filtration rate according to MDRD 
equation; ACE inhibitor: angiotensin-converting enzyme inhibitor; MRA: mineralocorticoid receptor antagonist; ECG: electrocardiogram; CK: creatine 
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Table 3 – Univariate and multivariate (corrected for age and gender) Cox regression analysis of clinical variables and long-term survival 
of patients with troponin elevation and non-acute coronary syndrome 
Univariate Cox regression Multivariate Cox Regression
HR (95% CI) p Value HR (95% CI) p Value
Age, y 1.040 (1.017–1.063) 0.001 1,030 (1,002–1,058) 0.038
Gender 0.899 (0.540–1.499) 0.684 0,807 (0,436–1,493) 0.494
CV risk factors
Diabetes mellitus 1.336 (0.783–2.277) 0.288
Hypertension 1.245 (0.658–2.358) 0.501
Previous CAD 1.067 (0.521–2.182) 0.860
Previous HF 1.649 (0.967–2.812) 0.066
GFR, mL/(min⋅1.73 m2) 0.992 (0.984–1.001) 0.082
Heart rate, bpm 1.006 (0.997–1.014) 0.193
Previous Medication
Antiplatelets 1.867 (1.230–2.835) 0.006 1,823 (1,105–3,006) 0.019
Beta-blockers 0.806 (0.459–1.416) 0.449
ACE inhibitors 0.689 (0.406–1.170) 0.170
MRA 0.764 (0.262–2.226) 0.611
Statins 1.017 (0.595–1.739) 0.950
ECG pattern 1.162 (0.999–1.351) 0.067
Laboratory
Isolated troponin elevation at the first 
evaluation
0.533 (0.311–0.916) 0.021 1.097 (0.378–3.180) 0.865
Isolated troponin elevation at the second 
evaluation
0.528 (0.218–1.279) 0.142
% troponin elevation at two sequential 
evaluations
1.000 (0.999–1.001) 0.750
Isolated troponin elevation at two 
sequential evaluations
0. 239 (0.111–0.512) <0.001 0.433 (0.196–0.958) 0.039
Hospitalization at index event 3.782 (1.794–7.973) <0.001 4.708 (1.652–13.423) 0.004
95% CI: 95% confidence interval; CAD: coronary artery disease; HF: Heart failure; GFR: glomerular filtration rate according to MDRD equation;  
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further damage occurs, the troponin present in the sarcomere 
is released into the circulation;8 previous studies advocated that 
reversibly injured cardiomyocytes could release troponin.29-31
CK-MB is also released when there is tissue necrosis, because 
of its high molecular weight (86kDa). Myoglobin has a rapid 
release, probably because of its low molecular weight (17kDa) 
and cytoplasmic location, and it could be released under 
myocardial stress without necrosis,8 just like troponin.
This molecular property of different MNMs could explain the 
incapacity of a single troponin I measurement to predict mortality 
in the present study and another one.32 This finding highlights 
the valuable role of CK-MB and myoglobin that cannot be 
accomplished by an isolated troponin measurement. However, 
current guidelines recommend that cardiac troponin be the only 
biomarker used for the diagnosis of ACS, owing to its superior 
sensitivity and accuracy.2,3 Nevertheless, failing to perform CK-MB 
and myoglobin measurements may come at a cost, especially 
for those patients who receive a non-ACS diagnosis. We believe 
that the exclusion of CK-MB and myoglobin from routine 
MNM evaluations in many institutions and guidelines should 
be reconsidered because of its superior adjunctive prognostic 
value, mainly in non-ACS patients, and the increased number of 
patients with troponin elevation that will be observed with highly 
sensitive troponin levels.
Limitations
Our institution follows a non-restrictive protocol for MNM 
measurement orders at the ED. Therefore, our rate of Non-ACS 
probably were increased, when compared with more strict 
protocols.
Our study analyzed patient mortality without considering 
that patients were managed differently according to the initial 
diagnosis. This may seem to be an important limitation, but 
it should be clarified that each clinical process usually has its 
own specific management, which influences patient prognosis. 
Therefore, the prognosis of the groups is somehow inherent to 
the provided management. For instance, patients with ACS are 
usually admitted for treatment with antiplatelet, anticoagulant 
agents, statins, revascularization, and other therapies, and this 
approach has a specific prognosis. 
Data were retrospectively collected and it is possible that some 
medical records were incomplete and the clinical history could 
have been undervalued.
The troponin assay previously used in our hospital was a 
contemporary assay called ‘sensitive troponin’ and it was not 
highly sensitive, unlike the currently used troponin assay, which 
is expected to detect positive troponin values in more patients, 
as described for this troponin assay.18,19 
Conclusion
High percentage of patients with an elevated troponin level 
measured in the ED were not diagnosed with ACS. These patients 
had a high-risk clinical profile, broad heterogeneity regarding 
the main diagnosis, and an adverse prognosis at 16 months. An 
isolated troponin I elevation in two consecutive determinations 
of MNM was a strong predictor of survival in non-ACS patients 
with troponin elevation.
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